BioNxt Receives Positive International Examination Report From the European Patent Office

Vancouver-based BioNxt Solutions Inc. has announced a positive report from the European Patent Office regarding its patent application for sublingual delivery of anticancer drugs aimed at treating autoimmune neurodegenerative diseases. The company expects the EU patent to be granted within eight weeks and plans to enter the national phase of the Patent Cooperation Treaty process in multiple countries, including the US, Canada, and China.

BioNxt is actively expanding its patent portfolio for orally dispersible films containing potent anticancer compounds. The company plans to file several related provisional patents in the EU, with protection potentially extending to 2045.

The firm’s lead program focuses on developing a proprietary Cladribine oral film for the multiple sclerosis market. With Cladribine tablets already approved in over 75 countries, the potential is significant, especially given the drug's 2023 sales exceeding one billion USD.

In addition to its MS program, BioNxt announced plans to pursue Myasthenia Gravis as a second clinical indication using ODF delivery systems. The global market for Myasthenia Gravis is expected to reach USD 6.7 billion by 2032.

The rising prevalence of Central Nervous System pathologies is expected to increase investment in new drug delivery systems. The market for CNS disease treatments is projected to reach USD 238.8 billion by 2032.